For patients with radiologically isolated syndrome (RIS) predictive of multiple sclerosis (MS), teriflunomide reduced the risk of a demyelinating event over a 2-year period in a phase 3 trial.
Researchers have identified specific regions of the brain that appear to be damaged by high blood pressure; the finding may explain the link between hypertension and cognitive impairment.